We are live on
!
Find out more
Los Angeles Capital Management Portfolio holdings
AUM
$27.2B
1-Year Est. Return
43.16%
This Fund
S&P 500
This Quarter
Est. Return
+13.16%
1 Year Est. Return
+43.16%
3 Year Est. Return
+177.72%
5 Year Est. Return
+262.7%
10 Year Est. Return
+1,121.27%
AUM
$22.5B
AUM Growth
+$1.93B
(+9.4%)
Cap. Flow
+$256M
Cap. Flow
% of AUM
1.14%
Top 10 Holdings %
Top 10 Hldgs %
26.61%
Holding
1,346
New
164
Increased
337
Reduced
605
Closed
194
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Visa
V
|
+$426M |
| 2 |
Deere & Co
DE
|
+$212M |
| 3 |
NVIDIA
NVDA
|
+$149M |
| 4 |
W.W. Grainger
GWW
|
+$140M |
| 5 |
Netflix
NFLX
|
+$135M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pfizer
PFE
|
+$196M |
| 2 |
Home Depot
HD
|
+$189M |
| 3 |
Gilead Sciences
GILD
|
+$145M |
| 4 |
Oracle
ORCL
|
+$145M |
| 5 |
Microsoft
MSFT
|
+$124M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 32.24% |
| 2 | Financials | 13.5% |
| 3 | Healthcare | 12.02% |
| 4 | Consumer Discretionary | 11.94% |
| 5 | Industrials | 11.18% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
651
Prestige Consumer Healthcare
PBH
$2.42B
| $1.06M | ﹤0.01% |
16,863
-5,658
| -25% | -$353K |
|
652
Protagonist Therapeutics
PTGX
$9.83B
| $1.05M | ﹤0.01% |
45,473
-31,517
| -41% | -$529K |
|
653
Patterson-UTI
PTEN
$4.15B
| $1.05M | ﹤0.01% |
89,383
+71,711
| +406% | +$1.05M |
|
654
Enova International
ENVA
$6.56B
| $1.04M | ﹤0.01% |
23,504
-18,121
| -44% | -$822K |
|
655
Merchants Bancorp
MBIN
$2.54B
| $1.04M | ﹤0.01% |
39,950
-590
| -1% | -$16.3K |
|
|
TWOU
656
DELISTED
2U Inc
TWOU
| $1.04M | ﹤0.01% |
5,052
+3,211
| +174% | +$803K |
|
657
Metropolitan Bank Holding Corp
MCB
$1.16B
| $1.03M | ﹤0.01% |
30,535
-2,732
| -8% | -$142K |
|
658
Helmerich & Payne
HP
$4.27B
| $1.03M | ﹤0.01% |
28,873
+23,188
| +408% | +$1M |
|
|
WW
659
DELISTED
WW International
WW
| $1.03M | ﹤0.01% |
250,083
+105,808
| +73% | +$463K |
|
660
ESCO Technologies
ESE
$7.73B
| $1.03M | ﹤0.01% |
+10,752
| New | +$998K |
|
661
Parker-Hannifin
PH
$133B
| $1.03M | ﹤0.01% |
3,050
+2,089
| +217% | +$692K |
|
662
Grid Dynamics Holdings
GDYN
$646M
| $1.02M | ﹤0.01% |
88,873
-4,098
| -4% | -$48.1K |
|
663
Quanex
NX
$980M
| $1.02M | ﹤0.01% |
47,207
-2,119
| -4% | -$50.9K |
|
|
CNR
664
Core Natural Resources Inc
CNR
$4.63B
| $1.01M | ﹤0.01% |
17,312
-5,408
| -24% | -$308K |
|
665
Brady Corp
BRC
$4.42B
| $1.01M | ﹤0.01% |
18,767
+6,426
| +52% | +$336K |
|
|
OSG
666
Octave Specialty Group
OSG
$212M
| $1M | ﹤0.01% |
64,685
-47,815
| -43% | -$774K |
|
667
Cheniere Energy
LNG
$55.2B
| $1M | ﹤0.01% |
6,348
-5,981
| -49% | -$903K |
|
668
Talos Energy
TALO
$2.56B
| $998K | ﹤0.01% |
67,222
-3,108
| -4% | -$53.5K |
|
669
Univest Financial
UVSP
$1.18B
| $996K | ﹤0.01% |
41,937
-642
| -2% | -$17K |
|
670
Installed Building Products
IBP
$6.56B
| $995K | ﹤0.01% |
+8,730
| New | +$941K |
|
671
JB Hunt Transport Services
JBHT
$26.6B
| $993K | ﹤0.01% |
5,662
-1,527
| -21% | -$278K |
|
672
Evercore
EVR
$12B
| $993K | ﹤0.01% |
8,606
-230
| -3% | -$28.6K |
|
673
Amphastar Pharmaceuticals
AMPH
$855M
| $993K | ﹤0.01% |
26,475
+16,475
| +165% | +$540K |
|
674
CareDx
CDNA
$2.44B
| $989K | ﹤0.01% |
108,220
+5,988
| +6% | +$76.6K |
|
675
Helix Energy Solutions
HLX
$1.49B
| $988K | ﹤0.01% |
127,676
-2,567
| -2% | -$20.1K |
|
Similar funds
FDCDDQ
WP
N
PCH
VAI
Los Angeles Capital Management's Q1 2023 Portfolio in Review
As of Q1 2023, Los Angeles Capital Management held 1,346 positions worth $22.5B, up 9.4% from $20.6B the previous quarter. Its ten largest holdings account for 27% of the portfolio.
Los Angeles Capital Management's Q1 2023 filing shows 164 new, 337 increased, 605 reduced and 194 closed positions. Its largest new stake was Bio-Rad Laboratories Class A: 184,796 shares worth $88.5M. The largest sale was Pfizer, an estimated $196M.
By sector, the portfolio is most concentrated in Technology at 32% of assets, up from 28% a quarter earlier, followed by Financials and Healthcare.
- Los Angeles Capital Management's largest Q1 2023 buy was Bio-Rad Laboratories Class A: 184,796 shares worth $88.5M.
- Los Angeles Capital Management added most to Visa in Q1 2023, an estimated $426M increase.
- Los Angeles Capital Management's biggest Q1 2023 reduction was Pfizer, cutting an estimated $196M.
- Los Angeles Capital Management fully exited Regions Financial in Q1 2023, selling an estimated $50.4M.
- Los Angeles Capital Management's ten largest holdings make up 27% of its $22.5B portfolio in Q1 2023.
- Los Angeles Capital Management opened 164 new positions and closed 194 in Q1 2023.
- Los Angeles Capital Management's portfolio value rose 9.4% quarter-over-quarter to $22.5B.
Based on Los Angeles Capital Management's 13F filing for Q1 2023, filed 4 May 2023.